Mesoblast Ltd (MESO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mesoblast Ltd (MESO) has a cash flow conversion efficiency ratio of -0.027x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.56 Million) by net assets ($574.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Mesoblast Ltd (MESO) net asset quality to measure how much of total assets are equity-financed.
Mesoblast Ltd - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Mesoblast Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Mesoblast Ltd (MESO) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Mesoblast Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mesoblast Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Awinic Technology Co Ltd
SHG:688798
|
0.068x |
|
Vardhman Textiles Limited
NSE:VTL
|
0.068x |
|
Jiangsu Cnano Technology Co Ltd
SHG:688116
|
0.024x |
|
Vukile Property Fund Ltd
JSE:VKE
|
0.030x |
|
Suzhou Jinhong Gas Co Ltd
SHG:688106
|
0.033x |
|
Aoshikang Technology Co Ltd Class A
SHE:002913
|
-0.001x |
|
Shenzhen Microgate Technology Co Ltd
SHE:300319
|
0.057x |
|
Ducommun Incorporated
NYSE:DCO
|
0.028x |
Annual Cash Flow Conversion Efficiency for Mesoblast Ltd (2005–2025)
The table below shows the annual cash flow conversion efficiency of Mesoblast Ltd from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Mesoblast Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $597.44 Million | $-49.95 Million | -0.084x | +17.12% |
| 2024-06-30 | $480.36 Million | $-48.46 Million | -0.101x | +19.98% |
| 2023-06-30 | $501.84 Million | $-63.27 Million | -0.126x | +4.74% |
| 2022-06-30 | $497.04 Million | $-65.78 Million | -0.132x | +27.87% |
| 2021-06-30 | $581.40 Million | $-106.68 Million | -0.183x | -78.83% |
| 2020-06-30 | $549.33 Million | $-56.37 Million | -0.103x | +14.59% |
| 2019-06-30 | $481.05 Million | $-57.79 Million | -0.120x | +12.56% |
| 2018-06-30 | $546.01 Million | $-75.01 Million | -0.137x | +25.64% |
| 2017-06-30 | $516.77 Million | $-95.47 Million | -0.185x | -10.89% |
| 2016-06-30 | $528.16 Million | $-88.00 Million | -0.167x | +16.58% |
| 2015-06-30 | $609.36 Million | $-121.71 Million | -0.200x | -39.49% |
| 2014-06-30 | $571.72 Million | $-81.86 Million | -0.143x | -66.87% |
| 2013-06-30 | $630.27 Million | $-54.08 Million | -0.086x | +43.03% |
| 2012-06-30 | $478.85 Million | $-72.12 Million | -0.151x | -171.78% |
| 2011-06-30 | $515.84 Million | $108.23 Million | 0.210x | +182.38% |
| 2010-06-30 | $37.92 Million | $-9.66 Million | -0.255x | +28.89% |
| 2009-06-30 | $25.79 Million | $-9.24 Million | -0.358x | -51.39% |
| 2008-06-30 | $26.22 Million | $-6.20 Million | -0.237x | +46.61% |
| 2007-06-30 | $20.54 Million | $-9.10 Million | -0.443x | -66.55% |
| 2006-06-30 | $11.97 Million | $-3.18 Million | -0.266x | -747.50% |
| 2005-06-30 | $19.26 Million | $-604.81K | -0.031x | -- |
About Mesoblast Ltd
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic… Read more